Skip to content

LifeSci IR

Investors
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

LifeSci IR

Investors

Press Releases

Choose Year
Search Press Releases

Found 211 Results

May 11, 2021

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

May 5, 2021

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

March 8, 2021

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

March 1, 2021

Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021

January 19, 2021

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

December 1, 2020

Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone

November 9, 2020

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

November 2, 2020

Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates

October 26, 2020

Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020

September 9, 2020

Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

«...4 567 8...20...»

IR Contact

FIRST NAME LAST NAME
COMPANY NAME
EMAIL@COMPANY.COM

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Unsubscribe

Loading...

Copyright © 2026 LifeSci IR | Powered by Astra WordPress Theme

Scroll to Top